In JAMA psychiatry, researchers outline new theories connecting antipsychotic use in people with schizophrenia and increased dementia risk.
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.
Research suggests that slowly tapering off an antipsychotic reduces the risk of withdrawal psychosis compared to abrupt discontinuation.
Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.
The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.
A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.
Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.
The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.
People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.
Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.
A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.
The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.
Researchers have found further evidence that the anticholinergic effect of psychiatric drugs can lead to cognitive impairments.
Researchers argue for a shift away from a focus on antipsychotic adherence toward understanding service users’ diverse patterns of use.
An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.
The CHR-P model focuses on “attenuated psychosis” to predict “transition” to schizophrenia and ignores other factors. But new research shows that the model is a poor predictor.
Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.
A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.
This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.
The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.
People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.
A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.
A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.
Researchers push for a renewed focus on true shared decision-making for patients diagnosed with psychosis.